MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

SectorGezondheidszorg

3.1 8.01

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.89

Max

3.18

Belangrijke statistieken

By Trading Economics

Inkomsten

-15M

-40M

Verkoop

8.2M

50M

Winstmarge

-80.43

Werknemers

435

EBITDA

-19M

-42M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+38.41% upside

Dividenden

By Dow Jones

Volgende Winsten

11 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-36M

1.1B

Vorige openingsprijs

-4.91

Vorige sluitingsprijs

3.1

Nieuwssentiment

By Acuity

50%

50%

168 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 apr 2026, 20:44 UTC

Winsten

Costco Reports 11% Growth in March Sales

8 apr 2026, 23:51 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 apr 2026, 23:51 UTC

Marktinformatie

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8 apr 2026, 23:36 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Lower on Likely Technical Correction -- Market Talk

8 apr 2026, 22:56 UTC

Marktinformatie

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8 apr 2026, 22:45 UTC

Marktinformatie

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8 apr 2026, 22:17 UTC

Marktinformatie

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8 apr 2026, 21:52 UTC

Belangrijke Nieuwsgebeurtenissen

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8 apr 2026, 21:24 UTC

Winsten

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8 apr 2026, 21:01 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

8 apr 2026, 20:43 UTC

Acquisities, Fusies, Overnames

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8 apr 2026, 20:43 UTC

Acquisities, Fusies, Overnames

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8 apr 2026, 20:43 UTC

Acquisities, Fusies, Overnames

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8 apr 2026, 20:42 UTC

Acquisities, Fusies, Overnames

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8 apr 2026, 20:42 UTC

Acquisities, Fusies, Overnames

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8 apr 2026, 20:42 UTC

Acquisities, Fusies, Overnames

Oracle Responds to TRC Cap Mini-Tender Offer

8 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 apr 2026, 20:11 UTC

Acquisities, Fusies, Overnames

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8 apr 2026, 20:11 UTC

Acquisities, Fusies, Overnames

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8 apr 2026, 20:11 UTC

Acquisities, Fusies, Overnames

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8 apr 2026, 19:44 UTC

Winsten

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8 apr 2026, 19:16 UTC

Marktinformatie

Hogs Follow Cutout Prices Lower -- Market Talk

8 apr 2026, 19:02 UTC

Marktinformatie

Global Energy Roundup: Market Talk

8 apr 2026, 19:02 UTC

Marktinformatie

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8 apr 2026, 18:58 UTC

Marktinformatie

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8 apr 2026, 18:51 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 apr 2026, 18:51 UTC

Marktinformatie

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8 apr 2026, 18:14 UTC

Belangrijke Nieuwsgebeurtenissen

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8 apr 2026, 18:05 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

38.41% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD  38.41%

Hoogste 5 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

168 / 349 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat